Currently there is no single medication that can be administered locally in the esophagus. EsoCap develops a smart application technology allowing a targeted drug delivery in the esophagus with prolonged mucosal contact time and controlled release of APIs. The EsoCap technology addresses a major need expressed by international KOLs. Our business model is to show clinical feasibility in one indication and to seek a partner.
Presenter: Isabelle Racamier, CEO, EsoCap AG